PortalPublikationenFirst-line trastuzumab plus epirubicin and cyclophosphamide ...

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

Standard

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. / Untch, Michael; Muscholl, Michael; Tjulandin, Sergei; Jonat, Walter; Meerpohl, Hans-Gerd; Lichinitser, Mikhail; Manikhas, Alexey G; Coumbos, Alexandra; Kreienberg, Rolf; Andreas, Du Bois; Harbeck, Nadia; Jackisch, Christian; Müller, Volkmar; Pauschinger, Matthias; Thomssen, Christoph; Lehle, Michaela; Catalani, Olivier; Lück, Hans-Joachim.

in: J CLIN ONCOL, Jahrgang 28, Nr. 9, 9, 2010, S. 1473-1480.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Untch, M, Muscholl, M, Tjulandin, S, Jonat, W, Meerpohl, H-G, Lichinitser, M, Manikhas, AG, Coumbos, A, Kreienberg, R, Andreas, DB, Harbeck, N, Jackisch, C, Müller, V, Pauschinger, M, Thomssen, C, Lehle, M, Catalani, O & Lück, H-J 2010, 'First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.', J CLIN ONCOL, Jg. 28, Nr. 9, 9, S. 1473-1480. <http://www.ncbi.nlm.nih.gov/pubmed/20177030?dopt=Citation>

APA

Untch, M., Muscholl, M., Tjulandin, S., Jonat, W., Meerpohl, H-G., Lichinitser, M., Manikhas, A. G., Coumbos, A., Kreienberg, R., Andreas, D. B., Harbeck, N., Jackisch, C., Müller, V., Pauschinger, M., Thomssen, C., Lehle, M., Catalani, O., & Lück, H-J. (2010). First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J CLIN ONCOL, 28(9), 1473-1480. [9]. http://www.ncbi.nlm.nih.gov/pubmed/20177030?dopt=Citation

Vancouver

Untch M, Muscholl M, Tjulandin S, Jonat W, Meerpohl H-G, Lichinitser M et al. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J CLIN ONCOL. 2010;28(9):1473-1480. 9.

Bibtex

@article{93acc5ebf9d84e53a48aef1b9116e648,
title = "First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.",
abstract = "A high incidence of congestive heart failure (CHF) has been observed in patients with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and trastuzumab. The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial evaluated trastuzumab plus cyclophosphamide and the less cardiotoxic anthracycline epirubicin.",
author = "Michael Untch and Michael Muscholl and Sergei Tjulandin and Walter Jonat and Hans-Gerd Meerpohl and Mikhail Lichinitser and Manikhas, {Alexey G} and Alexandra Coumbos and Rolf Kreienberg and Andreas, {Du Bois} and Nadia Harbeck and Christian Jackisch and Volkmar M{\"u}ller and Matthias Pauschinger and Christoph Thomssen and Michaela Lehle and Olivier Catalani and Hans-Joachim L{\"u}ck",
year = "2010",
language = "Deutsch",
volume = "28",
pages = "1473--1480",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

RIS

TY - JOUR

T1 - First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.

AU - Untch, Michael

AU - Muscholl, Michael

AU - Tjulandin, Sergei

AU - Jonat, Walter

AU - Meerpohl, Hans-Gerd

AU - Lichinitser, Mikhail

AU - Manikhas, Alexey G

AU - Coumbos, Alexandra

AU - Kreienberg, Rolf

AU - Andreas, Du Bois

AU - Harbeck, Nadia

AU - Jackisch, Christian

AU - Müller, Volkmar

AU - Pauschinger, Matthias

AU - Thomssen, Christoph

AU - Lehle, Michaela

AU - Catalani, Olivier

AU - Lück, Hans-Joachim

PY - 2010

Y1 - 2010

N2 - A high incidence of congestive heart failure (CHF) has been observed in patients with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and trastuzumab. The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial evaluated trastuzumab plus cyclophosphamide and the less cardiotoxic anthracycline epirubicin.

AB - A high incidence of congestive heart failure (CHF) has been observed in patients with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and trastuzumab. The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial evaluated trastuzumab plus cyclophosphamide and the less cardiotoxic anthracycline epirubicin.

M3 - SCORING: Zeitschriftenaufsatz

VL - 28

SP - 1473

EP - 1480

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 9

M1 - 9

ER -